regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
== Business model == In the period between 2006 and 2014, the company transitioned from print-centric to digital media, increasing digital revenues from 11% to 50% of total revenues. The company's growth during this period came from both "organic" growth and strategic acquisitions. In 2009 the firm was described as a "business to business magazine publisher", which could be interpreted as a publisher of trade magazines. In 2018, the organization transitioned fully from a digital media organization to a digital marketing organization, following market trends. As such, the company changed its name from Advantage Business Media to Advantage Business Marketing, updated its logo, and began the overhaul of its digital websites and assets. The organization offered digital marketing services including inbound marketing, branding, automation services, customer relationship management integration, and data management.
2 CO(NH2)2 → HN(CONH2)2 + NH3 Under related conditions, pyrolysis of urea affords triuret O=C(−N(H)−C(=O)−NH2)2. In general, organic biurets (those with alkyl or aryl groups in place of one or more H atoms) are prepared by trimerization of isocyanates. For example, the trimer of 1,6-hexamethylene diisocyanate is also known as HDI-biuret. In the anhydrous form, the molecule is planar and unsymmetrical in the solid state owing to intramolecular hydrogen bonding. The terminal C–N distances of 1.327 and 1.334 Å are shorter than the internal C–N distances of 1.379 and 1.391 Å. The C=O bond distances 1.247 and 1.237 Å. It crystallizes from water as the monohydrate.
== Surrogate endpoint == A surrogate endpoint (or marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but doesn't necessarily have a guaranteed relationship. The National Institutes of Health (USA) define surrogate endpoint as "a biomarker intended to substitute for a clinical endpoint".
The poor taste and lack of sugar in modern garden and commercial tomato varieties resulted from breeding tomatoes to ripen uniformly red. This change occurred after the discovery of a mutant "u" phenotype in the mid-20th century, so named because the fruits ripened uniformly. This was widely cross-bred to produce red fruit without the typical green ring around the stem on un-crossbred varieties. Before this, most tomatoes produced more sugar during ripening, and were sweeter and more flavorful. 10–20% of the total carbon fixed in the fruit can be produced by photosynthesis in the developing fruit of the normal U phenotype. The u mutation encodes a factor that produces defective chloroplasts with lower density in developing fruit, making them a lighter green, and reducing sugar in the resulting ripe fruit by 10–15%. Perhaps more importantly, the fruit chloroplasts are remodelled during ripening into chlorophyll-free chromoplasts that synthesize and accumulate the carotenoids lycopene, β-carotene, and other metabolites that are sensory and nutritional assets of the ripe fruit. The potent chloroplasts in the dark-green shoulders of the "U" phenotype are beneficial here, but have the disadvantage of leaving green shoulders near the stems of the ripe fruit, and even cracked yellow shoulders. This is apparently because of oxidative stress due to overload of the photosynthetic chain in direct sunlight at high temperatures. Hence, genetic design of a commercial variety that combines the advantages of types "u" and "U" requires fine-tuning, but may be feasible.
=== Mutations === Mutations in myostatin do more than just affect the amount of muscle mass an organism can produce; they also have variable effects on other phenotypes for different species. For example, a Belgian Blue bovine with a mutation that inhibits myostatin production will exhibit a dramatic increase in muscle mass but will also lead to dystocia. Other species with myostatin deficiency mutation such as humans or Whippet dogs do not get obstructed labor.
Sources: en.wikipedia.org
== History == Gordon C. Sharp first described mixed connective tissue disease (MCTD) in 1972 as an entity with mixed features of systemic sclerosis (SSc), systemic lupus erythematosus (SLE), polymyositis/dermatomyositis (PM/DM), and rheumatoid arthritis (RA) along with an elevated level of high-titre anti-U1small nuclear (sn) anti-ribonucleoprotein (anti-RNP) antibodies.
doi:10.1038/s41443-022-00636-7. PMID 36307732. Rushton, J.Philippe; Bogaert, Anthony F (1987). "Race differences in sexual behavior: Testing an evolutionary hypothesis". Journal of Research in Personality. 21 (4): 529–51. doi:10.1016/0092-6566(87)90038-9. Sutherland, Ronald S; Kogan, Barry A; Baskin, Laurence S; Mevorach, Robert A; Conte, Felix; Kaplan, Selna L; Grumbach, Melvin M (1996). "The Effect of Prepubertal Androgen Exposure on Adult Penile Length". The Journal of Urology. 156 (2): 783–7, discussion 787. doi:10.1016/S0022-5347(01)65814-2. PMID 8683783.
In 1813, Lieutenant-Colonel, Sir Thomas Sydney Beckwith arrived in Bermuda to command a force tasked with raiding the Atlantic Seaboard of the United States, specifically in the region of Chesapeake Bay, with the 102d Regiment's Commanding Officer, Lieutenant-Colonel Charles James Napier, as his Second-in-Command. Beckwith split the force into two brigades. One, was the 102d Regiment, Royal Marines from the Bermudian naval base, and two companies recruited from French prisoners-of-war that had been sent to reinforce the Bermuda garrison, was under Napier's command, and the other under Lieutenant-Colonel Williams of the Royal Marines. Embarking aboard naval vessels engaged on the American coast on the 8 June 1813, they took part in the Battle of Craney Island on 22 June 1813. On 8 August 1813, 15 British ships blockaded the mouth of the Patapsco River as part of a ruse to make the Americans believe Baltimore was under threat. After a few days the ships headed south towards Annapolis. However, Rear Admiral George Cockburn believed Annapolis too heavily defended, and instead had the 102d Regiment and Royal Marines construct a base on Kent Island. The 102d Regiment fought a small skirmish against local militia on the island, before assisting with construction of the base. After carrying out raids on the Atlantic coast of the United States, and minus the two companies of Frenchmen, they left the Chesapeake and landed at Halifax, Nova Scotia, on 20 September 1813.
=== Compressibility === The compressibility of a salt is strongly determined by its structure, and in particular the coordination number. For example, halides with the caesium chloride structure (coordination number 8) are less compressible than those with the sodium chloride structure (coordination number 6), and less again than those with a coordination number of 4.
David Baker online talk: "Crowd Sourcing Protein Folding: Rosetta@Home and FoldIt" Archived July 2, 2017, at the Wayback Machine David Baker online seminar: "Introduction to Protein Design" Archived April 1, 2016, at the Wayback Machine David Baker online seminar: "Design of New Protein Functions" Archived April 1, 2016, at the Wayback Machine
Sources: en.wikipedia.org
== Ligand properties == Several principles and trends are illustrated by the case of complexes of dimethylformamide (DMF), a very common amide ligand. Amides bind to metals through oxygen, which is the basic site of amides. Amides are thus L ligands according to the covalent bond classification method, i.e. charge-neutral 2e donors. With respect to HSAB theory, amides are classified as hard ligands. The M-O=C(NH2)H entity is planar in complexes of formamide. Similarly, the M-O=C(NC2)H entity is planar in complexes of DMF. Two geometrically distinct bonding modes are possible depending on the relative positions of the metal ion and the N-substituent on the amide. For simple unidentate amides, like DMF, the M and N are transoid.
=== Pharmacokinetics === Peak levels of tavapadon are reached after approximately 2 to 4 hours with oral administration. It shows dose-proportional pharmacokinetics across its maintenance dosage range. Food does not significantly modify the pharmacokinetics of tavapadon and it can be taken without regard for food. The volume of distribution of tavapadon is 63.5 L. Its plasma protein binding is 93%, primarily to albumin. Tavapadon is primarily metabolized by CYP3A4. It has a major inactive metabolite. Unchanged tavapadon is excreted less than 1% in urine and feces. Its major inactive metabolite was excreted less than 5% in urine and feces. The elimination half-life of tavapadon is 25.5 hours.
Portuguese is the official and predominantly spoken language in Portugal. It is one of 24 official and working languages of the European Union. Portuguese is the fifth-most widely spoken first language in the world, with around 250 million native speakers. Portuguese Sign Language is officially protected by the country's constitution. The recognised regional languages and dialects include Mirandese, spoken in Terra de Miranda, and Barranquenho, in Barrancos. Portuguese people are typically bilingual, with 67.5% speaking at least two languages, and tend to be proficient non-native English speakers, with Portugal placed sixth globally for English proficiency in the 2025 EF English Proficiency Index.
==== Blue Dream ==== Blue Dream is a hybrid cannabis strain widely used for both medical and recreational purposes, developed in 2003 through mixing Sativa and Indica strains named Blueberry and Haze. Believed to have originated in California, the plants will typically grow within 9-10 weeks, with moderate to high yields.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.